Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Double-blind, Randomised, Single-dose, Parallel Group Study to Demonstrate the Equivalent Pharmacokinetic Properties of a Single Intravenous Dose of HD204 and Bevacizumab (Avastin) in Healthy Male Subjects

Trial Profile

A Phase I, Double-blind, Randomised, Single-dose, Parallel Group Study to Demonstrate the Equivalent Pharmacokinetic Properties of a Single Intravenous Dose of HD204 and Bevacizumab (Avastin) in Healthy Male Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Pharmacokinetics
  • Acronyms SAMSON; Samson1
  • Sponsors Prestige BioPharma
  • Most Recent Events

    • 31 May 2020 Results assessing quality and clinical similarity (pharmacokinetic and safety) of HD204 in healthy males, presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
    • 08 Jul 2019 Primary endpoint has been met. (Area under Curve (AUC, Pharmacokinetics)), according to a Prestige BioPharma media release.
    • 08 Jul 2019 According to a Prestige BioPharma media release, the top line results from this study will be presented at the ESMO 2019.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top